通过通过ERK-MAPK通路对PD-L1进行上调,ANLN促进了头部和部状细胞癌的进展
Lei Wang1, Junrong Wang1, Nana Wang2
1Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang, P.R. China.
iScience
|February 19, 2025
概括
在头部和部癌症中静止素 (ANLN) 抑制瘤生长和PD-L1表达. 将ANLN沉默与抗PD-1疗法结合起来,可以增强抗瘤免疫力,抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 素 (ANLN) 对于细胞分裂和细胞骨组织至关重要.
- 头部和部状细胞癌 (HNSCC) 的进展涉及复杂的分子和免疫相互作用.
- 瘤免疫微环境显著影响HNSCC治疗结果.
研究的目的:
- 研究ANLN在HNSCC进展中的作用及其对瘤免疫微环境的影响.
- 评估将ANLN沉默与抗编程细胞死亡蛋白1 (PD-1) 治疗相结合的疗效.
- 探索ANLN在HNSCC中的功能背后的分子机制.
主要方法:
- 在体外和体外HNSCC的实验模型.
- 对临床HNSCC标本的分析.
- 基因沉默技术以减少ANLN表达.
- 免疫组织化学和流动细胞测量以评估免疫细胞透和激活.
- 西方模糊分析信号通路激活.
主要成果:
- 通过安静ANLN,可以抑制HNSCC细胞的增殖和迁移.
- 沉默ANLN降低了细胞外信号调节激酶-线原激活蛋白激酶 (ERK-MAPK) 途径的激活.
- ANLN沉默导致瘤细胞上编程死亡联体-1 (PD-L1) 表达的减少.
- 结合ANLN沉默和抗PD-1疗法显著增强CD8+T细胞激活和瘤透.
- 组合疗法在体内显著抑制了HNSCC瘤生长.
结论:
- 在HNSCC的进展和免疫逃避中,ANLN起着重要作用.
- 向ANLN可以通过减少PD-L1表达来调节瘤免疫微环境.
- 将ANLN沉默与抗PD-1疗法结合起来,是HNSCC治疗的一个有希望的策略.
- 在HNSCC中,ANLN是增强免疫治疗疗效的潜在治疗标.
相关概念视频
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


